The Trump effect: PwC report says the FDA has slammed the brakes on significant new drug regulations
Donald Trump launched his presidency breathing fire on federal regulations. And the top officials at the FDA heard that call loud and clear.
A new report out from PricewaterhouseCoopers shows that the agency reined in its issuance of new federal regulations to a 20-year low in 2017, as the Scott Gottlieb stepped up to the helm as commissioner.
Instead, the agency has shifted to new guidances in preference to hardline regulations, says PwC. And that will likely come as a welcome emphasis in the biopharma industry, where we’ve seen the FDA repeatedly demonstrate its willingness to relax old standards to accelerate new drug development.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.